{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T11:07:54.238298+00:00","company":{"ticker":"AEMD","cik":882291,"company_name":"AETHLON MEDICAL INC"},"pagination":{"limit":100,"returned":8,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"governance_change","fact_key":"565f247c46cffe6db4d12931176d0cc45884a69c","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2026-02-23T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2026-02-19","item_codes_triggered":["5.03"],"summary_text":"Increased authorized shares of common stock from 6,000,000 to 100,000,000."},"claim":"AETHLON MEDICAL INC: Increased authorized shares of common stock from 6,000,000 to 100,000,000 (effective 2026-02-19).","evidence_excerpt":"Our Board previously approved the amendment of our Articles of Incorporation, as amended, to increase the number of authorized shares of our common stock, par value $0.001 per share, from 6,000,000 shares to 100,000,000 shares (the “Articles Amendment”). As reported in Item 5.07 below, on February 19, 2026, our stockholders approved the Articles Amendment. The Articles Amendment was filed with the Secretary of State of the State of Nevada on February 19, 2026.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-26-001259","anchor_url":"https://secwatch.observer/filing/0001683168-26-001259#claim-565f247c46cffe6db4d12931176d0cc45884a69c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316826001259/0001683168-26-001259-index.htm"},{"fact_type":"material_agreement","fact_key":"16c4c3c843a3edf3a6d149fb99cd7a4eb33a21fe","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2026-01-26T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Pre-Funded Common Stock Purchase Warrant","agreement_type":"equity_purchase","counterparty":"institutional investor","effective_date":"2026-01-22","item_codes_triggered":["1.01"],"value_text":"Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa"},"claim":"AETHLON MEDICAL INC amended Amendment to Pre-Funded Common Stock Purchase Warrant with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).","evidence_excerpt":"Also on January 22, 2026, the Company and the Purchaser entered into the Amendment to Pre-Funded Common Stock Purchase Warrant (the “PFW Amendment”). The PFW Amendment amends the terms of that certain Pre-Funded Common Stock Purchase Warrant by and between the Company and the Purchaser dated December 8, 2025 (the “Warrant”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The PFW Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001683168-26-000528","anchor_url":"https://secwatch.observer/filing/0001683168-26-000528#claim-16c4c3c843a3edf3a6d149fb99cd7a4eb33a21fe","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316826000528/0001683168-26-000528-index.htm"},{"fact_type":"material_agreement","fact_key":"2d860d78630f012ffe29b6831a2ae80b23a54902","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2026-01-26T23:59:59+00:00","payload":{"action":"amendment","agreement_name":"Amendment to Securities Purchase Agreement","agreement_type":"equity_purchase","counterparty":"institutional investor","effective_date":"2026-01-22","item_codes_triggered":["1.01"],"value_text":"Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa"},"claim":"AETHLON MEDICAL INC amended Amendment to Securities Purchase Agreement with institutional investor valued at Amendment removed requirement that Company obtain shareholder approval for exercise of pre-funded wa (effective 2026-01-22).","evidence_excerpt":"On January 22, 2026, Aethlon Medical, Inc. (the “Company”) and an institutional investor (the “Purchaser”) entered into the Amendment to Securities Purchase Agreement (the “SPA Amendment”). The SPA Amendment amends the terms of that certain Securities Purchase Agreement by and between the Company and the Purchaser dated December 5, 2025 (the “Securities Purchase Agreement”), as previously disclosed on the Current Report on Form 8-K filed by the Company on December 8, 2025. The SPA Amendment removed the requirement that Company obtain shareholder approval of issuance or exercise the pre-funded warrants under Nasdaq 5635 prior to those pre-funded warrants becoming exercisable. As a result, the pre-funded warrants are immediately exercisable. All other terms of the Securities Purchase Agreement remain unchanged.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001683168-26-000528","anchor_url":"https://secwatch.observer/filing/0001683168-26-000528#claim-2d860d78630f012ffe29b6831a2ae80b23a54902","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316826000528/0001683168-26-000528-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"a88cbd8371e00b2521d8d85912c23323cf2eb001","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2025-10-22T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"hearing_requested","cure_deadline":null,"deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":null,"minimum_requirement":null,"notice_date":"2025-10-16","notice_type":"deficiency_notice","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"],"rules_cited_in_text":true},"claim":"AETHLON MEDICAL INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"October 16, 2025, Aethlon Medical, Inc. (the\n“Company”) received a notification letter (the “Notice”) from the Listing Qualifications Department (the “Staff”)\nof the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s\ncommon stock was below $1.00 per share for 30 consecutive business days, the Company was not in compliance with the minimum bid price\nrequirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Marketplace Rule 5550(a)(2) (the “Minimum\nBid Price Requirement”) and subject to the compliance and de","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-007719","anchor_url":"https://secwatch.observer/filing/0001683168-25-007719#claim-a88cbd8371e00b2521d8d85912c23323cf2eb001","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316825007719/0001683168-25-007719-index.htm"},{"fact_type":"governance_change","fact_key":"b3b3caf4a08a8ee2e1f900c34790a129680ce6a1","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2025-10-16T23:59:59+00:00","payload":{"change_type":"charter_amendment","effective_date":"2025-10-16","item_codes_triggered":["5.03"],"summary_text":"Filed a Certificate of Change with the Nevada Secretary of State to effect a 1-for-10 reverse stock split of common stock, reducing authorized shares from 60,000,000 to 6,000,000, effective at 10:00 a.m. ET on October 16, 2025."},"claim":"AETHLON MEDICAL INC: Filed a Certificate of Change with the Nevada Secretary of State to effect a 1-for-10 reverse stock split of common stock, reducing authorized shares from 60,000,000 to 6,000,000, effective at 10:00 a.m. ET on October 16, 2025 (effective 2025-10-16).","evidence_excerpt":"On October 14, 2025, Aethlon Medical, Inc., a Nevada corporation (the “Company”), filed a Certificate of Change (the “Certificate of Change”) pursuant to Section 78.209 of the Nevada Revised Statutes (“NRS”) with the Secretary of State of the State of Nevada authorizing a 1-for-10 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, $0.001 par value per share (the “Common Stock”).","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-007586","anchor_url":"https://secwatch.observer/filing/0001683168-25-007586#claim-b3b3caf4a08a8ee2e1f900c34790a129680ce6a1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316825007586/0001683168-25-007586-index.htm"},{"fact_type":"exchange_compliance_notice","fact_key":"b4757bd22433d48076322a25b6015abbf60e713d","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2025-01-08T23:59:59+00:00","payload":{"company_response":null,"compliance_status":"extension_granted","cure_deadline":"2025-06-23","deficiency_type":"minimum_bid_price","delisting_effective_date":null,"exchange":"nasdaq","hearing_date":null,"immediate_listing_effect":false,"minimum_requirement":null,"notice_date":"2025-01-07","notice_type":"extension_granted","plan_due_date":null,"raw_rule_text":null,"reported_value":null,"rule_numbers":["5550(a)(2)","5810(c)(3)(A)"]},"claim":"AETHLON MEDICAL INC received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).","evidence_excerpt":"January 7, 2025, the\nCompany received a letter from Nasdaq (the “Extension Notice”) advising that the Company has been granted a 180-day extension,\nor until June 23, 2025, to regain compliance with the Minimum Bid Price","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-000150","anchor_url":"https://secwatch.observer/filing/0001683168-25-000150#claim-b4757bd22433d48076322a25b6015abbf60e713d","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316825000150/0001683168-25-000150-index.htm"},{"fact_type":"executive_change","fact_key":"b0d01dd42b","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2024-10-03T23:59:59+00:00","payload":{"action":"departed","action_category":"departure","departure_tone":"routine","effective_date":"2024-10-03","interim":false,"role":"Chief Operating Officer","role_category":"coo","successor_name":null,"successor_named":false},"claim":"Guy F. Cipriani departed as Chief Operating Officer at AETHLON MEDICAL INC.","evidence_excerpt":"Guy F. Cipriani, Chief Operating Officer of the Company, has departed the Company.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001683168-24-006896","anchor_url":"https://secwatch.observer/filing/0001683168-24-006896#claim-b0d01dd42b","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316824006896/0001683168-24-006896-index.htm"},{"fact_type":"executive_change","fact_key":"aea9b9e4e1","cik":882291,"ticker":"AEMD","company_name":"AETHLON MEDICAL INC","filed_at":"2024-10-03T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2024-10-03","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"James B. Frakes was appointed as Chief Executive Officer at AETHLON MEDICAL INC.","evidence_excerpt":"appointed James B. Frakes to serve as the Company’s permanent Chief Executive Officer","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001683168-24-006896","anchor_url":"https://secwatch.observer/filing/0001683168-24-006896#claim-aea9b9e4e1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/882291/000168316824006896/0001683168-24-006896-index.htm"}]}